Greetings, and welcome to the 3D Systems Third Quarter 2024 Earnings Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Mick McCloskey, Vice President, Investor Relations. Please go ahead, Mick.

Hello, and welcome to 3D Systems' third quarter 2024 conference call. With me on today's call are Dr. Jeffrey Graves, President and CEO, and Jeff Creech, EVP and CFO. The webcast portion of this call contains a slide presentation that we will refer to during the call. Those following along on the phone who wish to access the slide portion of this presentation may do so on the Investor Relations section of our website. The following discussion and responses to your questions reflect management's views as of today only and will include forward-looking statements as described on this slide. Actual results may differ materially. Additional information about factors that could potentially impact our financial results is included in our latest press release and our recent filings with the SEC, including our most recent annual report on Form 10-K and quarterly reports on Form 10-Q. During this call, we will discuss certain non-GAAP measures. In our press release and slides accompanying this webcast, you'll find additional disclosures regarding these non-GAAP measures, including reconciliations with comparable GAAP measures. Finally, unless otherwise stated, all comparisons in this call will be against our results for the comparable periods of 2023. With that, I'll turn the call over to our CEO, Jeff Graves, for opening remarks.

Thank you, Mick, and good morning, everyone. Today, I'll begin with an overview of our third quarter results and then touch on some recent key accomplishments and announcements. I'll then ask our CFO, Jeff Creech, to take us through the Q3 in greater detail before closing the call with comments on our outlook, after which we're happy to take questions. So let's start on Slide 5. At a high level, our third quarter revenue largely represents a continuation of the trends that we and the additive industry broadly have been contending with for several quarters now. Very simply, macroeconomic and geopolitical uncertainties have caused our customers to reduce CapEx spending for new capacity in their factories, which in turn has created a persistent headwind to hardware system sales. It's really that simple. As a consequence, our revenues were essentially flat on a sequential basis. This was slightly weaker than we had anticipated as a few key installations of new systems, which were targeted for acceptance late in Q3, slipped into the fourth quarter. However, while the sale of new printing systems is still sluggish, what is changing for the better is the utilization rate of our installed base, as indicated by rising sales of consumables to our customers. Consumable materials grew approximately 10% from the prior year and demonstrated sustained sequential growth, a trajectory that has consistently improved since the beginning of the year, most recently growing 9% sequentially in the third quarter versus Q2. In a similar vein, interest in new application development has been on a very robust trajectory. As many of you know, we have one of the largest and most capable application engineering groups in the world. These engineers work directly with our customers on new applications for both metal and polymer 3D printing. Year-to-date, revenues from our industrial application group are up 26% from last year and continue to rise. We monitor this activity level as a directional indicator of growth potential for important new applications. The performance we experienced in Q3 is a strong indicator of continuing growth in customer interest in 3D printing for their production needs. We expect this interest to ultimately translate into more robust sales as the economic environment improves. To provide a little more color on where this interest is coming from, leading the way are what we refer to as the high reliability markets, such as energy, oil & gas, semiconductor equipment manufacturing, and aerospace and defense, all of which have a very high standard for component quality, performance, reliability, and traceability. For these customers, which are often subject to strict regulatory requirements, the ability of both our polymer and metal printing solutions to meet their needs and to do so with compelling economics is a cornerstone of our value proposition. As an example of markets that I'm particularly excited about these days are those driven by the $1 trillion investments being made in AI. These investments cascade directly into several of our targeted end markets, ranging from semiconductor equipment manufacturing to data centers to the power generation equipment needed to provide electricity critical to their operation. As just one example, the management of heat is absolutely essential to both the manufacture of silicon chips, as well as their performance and life in a data center environment. The nanoscale of advanced microprocessors, combined with the extraordinary number used in a modern data center, creates an extremely challenging environment to keep the processors cool in operation. One way to effectively do so is through the use of high purity copper elements that can be placed in or very near the heart of a GPU. Combining the inherent capability of 3D printing to manufacture complex, high surface area components with our unique capability to print ultra-high purity copper with our advanced metal printing systems gives GPU and data center architects a powerful means of removing heat effectively from the system. Given that the power consumed by data centers now exceeds that of many small countries, this cooling capability is increasingly valuable. And this is just one example of our increasing focus on the full semiconductor ecosystem that we believe will provide one avenue for meaningful growth for our company in the future. Another market we continue to be excited about is high-performance automotive, an example of which is F1 racing. As an example, you may have seen our announcement earlier this month with Sauber Motorsports. In this case, we updated the entire Sauber production facility, as they added 10 of our newest production printer systems to their manufacturing workflow. This included eight of our market-leading SLA 750 dual laser printers and two of our just-released PSLA 270 platform, all enabled by a host of industry-leading high-performance materials. Sauber will use these systems in large part to validate their aerodynamic designs through rapid fabrication of production components for wind tunnel testing. This award builds on a nearly 20-year relationship between our companies, reflecting the trust they have in our technological leadership and outstanding service capabilities, both of which are essential to their success in this challenging industry. This important win adds a strong new element to our automotive foundation, a market which is expected to grow to almost $8 billion in the next few years. Since I mentioned it, let me take a moment to focus on our newest photopolymer printing platform, the PSLA 270. This is the first of what will be a family of new projector-over-VAT printing systems, combining the superior surface quality associated with our flagship SLA printing platform with the blazing speeds offered by the latest high-resolution projector technology. This technology is an outgrowth of our work in regenerative medicine, which incorporates a very high-resolution projection system. By replacing a single point laser with a full-field projection system, we attain high precision at much higher print speeds. In fact, the closest competitive solution today would have to run two machines simultaneously to achieve the same output as one PSLA 270. In addition, this system is designed to use our entire portfolio of advanced polymers originally developed for the Figure 4 system. By offering this exceptional platform as a part of a complete factory workflow, we believe our PSLA platforms will lead the industry forward in photopolymer applications. From a healthcare standpoint, the third quarter was strong, with solid growth on a sequential and year-over-year basis. We attribute this growth to a meaningful recovery in dental, up well over 30%, and another impressive performance in personalized health care, which was up almost 20%. Given the momentum we have in our health care business broadly and our strong pipeline of new products and applications ahead, we remain very excited about the future of this portion of our business. From a gross margin standpoint, the third quarter was softer than we had anticipated, predominantly driven by an increase in inventory reserves and continued lower factory utilization, both driven by softness in printer volumes. Jeff Creech will take you through the specifics in more detail shortly, but after normalizing for inventory reserves, our third quarter operating margins were roughly in line with recent performance. We continue to target a business model that can deliver mid-40% margins or greater over time once the benefits of our insourcing and restructuring initiatives are fully realized with increasing volume. Operating expenses for the quarter were consistent with our expectations. We're pleased that our restructuring actions have started to more positively influence performance, representing a nearly $3 million sequential improvement. And while our overall OpEx expenses are declining, we continue to invest extensively in our R&D activities, which is fueling a historic year of product innovation for our company. More on this in just a few moments. While we're encouraged by some of the leading indicators that we're now seeing, we also recognize that the revenue environment we're operating in today demands an even greater degree of operational efficiency to gain sustained profitability, which is our clear goal. As such, operating expenses remain a strong focus and a lever largely within our direct control in this environment. With that in mind, we maintain our goal of reducing operating expenses to below $6 million for the fourth quarter, with the majority of this improvement coming from reductions in G&A. Lastly, to our balance sheet, where we've been focused on optimizing working capital as we position ourselves for future growth. We entered 2024 with a goal to deliver inventory reductions as a healthy generator of cash throughout the year. Today, we remain on pace to reach our target of a 20% inventory reduction by year-end. Over the course of the third quarter, cash on our balance sheet declined $3 million from the prior quarter, a significant rate improvement from prior quarters. This leaves us with one of the strongest cash positions of any company in our industry. On Slide 6, I'd like to take a few moments to reflect on the historic year of progress across our technology roadmap. You've heard this from us many times before, but as the inventor of the technology that birthed the 3D printing industry, our dedication to innovation is a core element of our company culture. Maintaining momentum with mission-critical R&D, even though a challenging sales environment is not only fundamentally different than most of our peers, but it's embedded deeply in our DNA. This is the primary reason customers turn to 3D Systems first in assessing the capability of 3D printing to meet their metal and polymer production needs. Reflecting this commitment, you witnessed an unprecedented pace of innovation from our company over the last 12 months, contributing nearly 40 new materials, software enhancements, and metal and polymer printing platforms since Q3 of last year 25 in this year alone. And the momentum will continue as we exit this year and move into ‘25. This represents the culmination of three years of focus and investment as we're refreshing our entire portfolio of plant printing platforms and the materials and software that enable their outstanding production performance. From a key application standpoint, during the third quarter we announced QuickCast Air, which is targeted for the investment casting market. This casting method is essential to aircraft and rocket propulsion systems and other high-performance applications. It's expected to reach nearly $34 billion over the next 10 years. QuickCast Air reliably delivers a large, high-precision investment casting pattern in a fraction of the time and cost of traditional methods, providing up to a 50% reduction in resin usage in some cases, while maintaining the inherent advantage of virtually unlimited geometric complexity of design. The result for our customers is higher-performing components at lower cost and in much shorter production cycle times for their most demanding applications. On the software front, we announced a significant milestone in commercializing our Oqton Industrial MOS platform with our strategic partner, Baker Hughes. Our software, which is now utilized in Baker's Houston, Texas manufacturing facility, is enabling on-demand additive manufacturing to provide full factory floor workflow integration, automation, control, and optimization. Its production implementation is providing key proof points, such as a 98% reduction in active monitoring engineering time, a savings of 136 engineering hours per printer annually, and an 18% reduction in costs associated with scrap due to real-time actionable alerts during component production. Turning to healthcare, our personalized healthcare business delivered another quarter of meaningful growth. During the quarter, we were very pleased to announce that we are once again expanding our orthopedic surgical planning portfolio, this time with FDA clearance for our new total ankle patient-matched guides to pair with Smith & Nephew's total ankle replacement solution. This expands our patient-specific surgical solution capabilities in a market anticipated to grow to over $5 billion in the next few years. Today, we're exceptionally well positioned in the cranial, maxillofacial, and spinal markets, and new FDA-approved solutions such as this highlight our ability to expand our orthopedic applications much further in the human body. We're also leveraging our expertise in surgical solutions into adjacent markets, rolling out expanded capabilities to address the needs of trauma patients in addition. We see opportunities to expand our personalized health service in Europe and elsewhere and are investing accordingly to ensure regulatory approvals are acquired. These growth elements reinforce our enthusiasm about our growth in this key area of our company. For our dental activities, a key growth engine for the future is the multi-billion dollar dentures market. In an important milestone, we secured FDA clearance in September for our first-to-market multi-material single-piece jetted denture solution. Our unique denture offering provides unparalleled combination of toughness to ensure long-term reliability with outstanding aesthetics for enhanced patient experience. As previously shared, we found an excellent launch partner in Glidewell, one of the world's largest producers of restorative dental devices, who's hit the ground running with implementing jetted dentures into its workflow following our clearance with the FDA. We're excited to see this product enter the market in the coming months. To wrap up my introduction, undoubtedly 2024 has been a difficult sales environment. But with our strong balance sheet, we've delivered tremendous progress transforming our technology portfolio. Formnext, the largest AM conference of the year that was just held last week, gave us an opportunity to highlight this journey with the announcement of several new product introductions. In addition to our metal and PSLA polymer platforms, we highlighted our newest Titan Extrusion Platform, which is our inroad into the industrial extrusion printing market. The EXT family, as we call it, includes the 1270, the 1070, and our newest addition, the 800. Provides novel approach to extrusion technology, offering a hybrid solution that can accommodate pellets, filaments, and traditional CNC machining all in one platform. Delivering speeds of 5 times to 10 times faster and having raw material cost roughly 10 times lower than its closest competitor, we see increasing interest from our customers around the world for this family of products. Rounding things out, we've also announced a plethora of new materials supporting our SLA, NJP, and SLS platforms, further expanding the broadest portfolio of additive solutions in the industry and setting the stage for us to drive increased adoption in the years ahead. So with that I'll turn things over to our CFO Jeff Creech for more on the quarter.

Thank you, Jeff, and good morning everyone. I'll begin with our revenue summary on Slide 8. Third quarter revenues of $112.9 million declined 9% from prior year, driven primarily by a continuation of macroeconomic pressures impacting hardware system sales partially offset by growth in material sales. On a sequential basis, revenues were roughly flat and impacted by a few large dollar orders that fell outside of our third quarter close. Within our segments, industrial revenues were $57.9 million and down about 19%, predominantly driven mostly by a decline in printer sales. In our health care segment, revenues were $55.1 million for the quarter and grew 5% from prior year. As Jeff just mentioned, growth in the third quarter was primarily driven by a healthy rebound in dental and our personalized health care business. Now let's turn to Slide 9. Non-GAAP gross margin for the third quarter was 37.6% and included an increase in inventory obsolescence reserves taken in the quarter, representing approximately $3 million. Normalizing for the impact related to inventory reserves would result in a margin of 40.2% for the third quarter. Comparing to prior year, margin was 44.8%, which included a significant benefit of regenerative medicine milestone revenue recognition. Excluding the impacts of inventory reserve increases and the milestone recognition in the current and prior quarters, respectively, gross margins would have been 40.2% and 42.7%, with a year-on-year decline primarily driven by unfavorable absorption given lower sales volumes. Now let's move to Slide 10 for operating expense. Non-GAAP operating expense for the third quarter was $61.4 million, increasing $5.6 million from prior year, but declining $2.7 million consecutively, in line with our expectations. As an important reminder, the prior year quarter comparison benefited from a tailwind associated with lower incentive compensation expense in addition to other benefits that were more one-time in nature. Third quarter operating expense benefited from our previously discussed restructuring actions and we continue to expect an additional sequential reduction targeting OpEx below $60 million for the fourth quarter. Now to Slide 11 to finish up the P&L. We reported adjusted EBITDA of negative $14.3 million for the third quarter, compared to a gain of $4.7 million for the same quarter last year. Declines in adjusted EBITDA primarily reflect lower sales volumes, margin, and higher operating expenses as just discussed. The prior year profitability performance was also significantly impacted by the milestone revenue recognition from our RegMed business as I just mentioned. In line with my commentary on expected OpEx savings in the fourth quarter, we would also expect an improvement in adjusted EBITDA sequentially as we continue to move towards our longer-term goal of consistent profitability. For the third quarter, we reported a fully diluted loss per share of $1.35, and this includes non-cash charges of approximately $144 million associated with the impairment of goodwill and other long-lived assets as a result of our interim valuation testing during the third quarter of this year. This compared to a loss per share of $0.09 in the third quarter prior year. Non-GAAP loss per share was $0.12, compared to a gain per share of $0.01 in the prior year. Now to Slide 12 for the balance sheet. We closed the quarter with $190 million of cash and cash equivalents, compared to $193 million at the end of the second quarter of this year. As expected, cash performance represented an improvement in working capital management, particularly as we look to continue driving down inventories as a result of our insourcing actions from prior years. As noted on previous calls, we've been highly proactive in repurchasing our debt and have reduced our 0% convertible notes down by over 50% since Q3 of last year, fortifying our position to continue supporting critical R&D investments for the new product releases combined with a keen focus on reducing expenses to drive profitability. Looking forward, we continue to view inventory as a source of cash in the fourth quarter. I'll conclude my remarks on Slide 13. As you heard from us this morning, we continue to make strides across our portfolio to emerge stronger from the current economic cycle and pin up demand for additive solutions returns. We've been consistent in fueling our R&D engines through a tougher macro environment, driving an acceleration of applications and new product development to emerge stronger in the years ahead. However, we are adjusting our guidance expectations for the full-year 2024 as follows. We expect four-year revenues between the range of $440 million to $450 million, which implies a mid to high-single-digit percentage sequential recovery in the second-half revenues from the first-half of this year. While the fourth quarter has historically reflected a higher degree of year-end capital budget spending, given current uncertainty in the near-term, as well as indications of timing adjustments related to inventory management among a few customers, we expect the benefits to be more modest ending the year. Full-year gross margins are expected to be in the range of 38% to 40% given the impact of short-term inventory reserve adjustments as we continue to integrate our insourcing capabilities that we believe longer term will improve gross margins to the mid-40% range as volumes recover and we are able to reap the full benefits of our insourcing and restructuring actions. We are maintaining our expectations to deliver OpEx at or below $60 million for the fourth quarter, continuing its trend of sequential improvement and reflecting the benefits of our previous restructuring. As a result, adjusted EBITDA is expected to improve on a sequential basis, primarily driven by the reduction in operating expense. Jeff, I'll hand it back to you.

Thanks, Jeff. We believe that the broader macro trends negatively impacting our industry to the greatest extent are beginning now to move behind us. With our strong cash position we've been able to maintain our core investments for the future, while consistently restructuring our company to maximize operating efficiencies. Our determination to support key R&D investments are fundamentally different from many others in the industry, and we believe position us well for accelerated growth and profitability as our end markets inevitably strengthen. While we will not be providing explicit comments on 2025 yet, looking beyond this year, as much of our critical R&D work is behind us. We will continue to evaluate incremental actions that can strategically remove costs from our business and drive sustainable profitability. In doing so, I believe we'll deliver meaningful value to all of our stakeholders. So with that, we'll now open the line for questions. Kevin, if you'd open the line for us, please.

Certainly. We'll now be conducting a question-and-answer session. Our first question is coming from Jim Ricchiuti from Needham & Company. Your line is now live.

Hi, good morning. So I'm looking at your implied revenue guidance for Q4, it's a little surprising with only a month left in the quarter that there's a relatively wide range of scenarios. And I'm hoping you could help us understand what's driving that? I mean, it sounds like potentially, some of your customers may be working through inventories and maybe that's on the material side. But maybe if you could help us understand that a little and then I have a quick follow-up.

Yes, Jim, I think there's two factors. One of it clearly is inventory management from our customers. They're in good shape, but they want to make sure they don't get out over their skis with all the changes coming in '25 with the political environment and the geopolitical issues. I think nobody wants to be overly exposed on inventories. So I don't think it's a massive problem, but it's certainly they'll be managing them customer by customer. The big unknown, Jim, is really how much CapEx they'll be willing to spend in the fourth quarter and at what rate. Even if they cut loose CapEx late in the quarter, as we saw in Q3, some of those installations aren't then completed until the following quarter, which delays revenue recognition on many of them. So there can be a timing issue on their capital spend. In normal times, a lot of them would try to spend their capital up in the fourth quarter and get it done as early as possible for planning. Right now what we're seeing is a bit of trepidation, a bit of slowness in issuing POs. I expect this quarter to certainly be up, and but not quite, if I had to guess, Jim, not quite in line with historical norms. But there is some upside for us versus our midpoint. But given that Q3, there was some slippage at the end of the quarter, into the following quarter. I just don't want us to get out ahead of ourselves. So that's why you'd see a little bit of a wider range and a little bit more modesty, if you will, on the growth rate in Q4. So we believe it'll be up, and up nicely for the quarter. But CapEx inventory management are just unknowns, and we want to buffer for those.

Okay.

Does that make sense?

It's helpful. And maybe we could just turn to gross margins, because the guidance for the year, I guess 38%, 40%. Again, a little surprising given that your nine-month gross margin was 39.5%. Is this all a case of unfavorable absorption if the Q4 revenues come in at the low end of your implied guidance?

Yes, there are two factors, Jim. One of them is that, one of them is factory absorption. The other one really is mixed, because and I'm keeping my fingers crossed here. We should see an uptick in printer sales. And that's good for the long-term, from a materials utilization standpoint. I'm a little concerned that customers will be managing inventory on materials and it's an unknown. So you could see a mixed effect and you certainly will still see a factory utilization effect. So I'd say there's two factors in that. And both of them lead to a little modesty on the gross margin for the quarter. Nicely, the insourcing work we've done, I think, will pay real dividends for us from a printer manufacturing standpoint as volumes rise again, hopefully in '25. But for right now, any uptick in printer sales in Q4 would be a drag on gross margins.

Got it. Thank you.

Thanks, Jim, and have a good Thanksgiving.

Thank you. Next question is coming in from Greg Palm from Craig-Hallum. Your line is now live.

Good morning, Greg.

Yes, thanks. Hey, guys, this is Danny Eggerichs on for Greg today. Thanks for taking questions.

Hi, Danny. Sure.

I know you kind of said you're not going to touch on ‘25 yet, but just thinking about maybe profitability, I know in the release maybe some commentary was like trajectory towards profitability in quarters ahead? Are we thinking about it as something that can be a ’25 event? Or is it just kind of too early to tell how should we be thinking about break-even into profitability?

Yes, Danny, it's the art of prediction. I'm very encouraged by the number of new applications customers are discussing. If they invest real capital in these, we could see a significant increase in revenues in '25. The key factor is how quickly they'll allocate the funds. I'm confident that these applications are things they genuinely want to implement in their factories, which is promising. It's primarily a matter of timing. We are optimistic that revenues will rise in '25, which would be beneficial. Factory utilization is expected to improve, and our inventory reduction plan is great for cash flow, so those are all positive aspects. Additionally, we have genuine opportunities for cost management, which should be advantageous for '25. While I can't provide a specific number, I anticipate noticeable progress toward profitability in '25, and hopefully, at some point during the year, we will see a transition to positive EBITDA and growth from there. It's still too early to make definitive predictions, and we won't provide guidance until we release our fourth-quarter results, but I'm encouraged by the trends and we'll see whether they continue.

Yes, that makes total sense. Maybe if we can just touch on that AIG, the Application Innovation Group, sounds like was really strong in the quarter. Just maybe trying to size up that opportunity, maybe where contribution currently is? And when the cycle eventually turns, how should we be thinking about that opportunity moving forward?

And Danny, I would tell you that the revenue we generate from AIG. So these are obviously their applications customers are paying for us to develop with them. So there is a revenue stream there. The important thing about that is the trend of the revenue stream. So if it's growing, if not it may not be a material, we actually it may not be a material number on the overall P&L. But if it's growing, the customers are demanding more and more of our time to develop new applications. And we're picking and choosing those very carefully to make sure they're the highest volume, highest value components that we can help them develop for their factories. So I would tell you the magnitude of revenue is not really important. It's the direction that is headed in that 26%, I think we've quoted a 26% rise is fabulous. I mean our guys are swamped and we have 80-plus applications here is the biggest I believe it's the biggest in the industry is certainly I'm very proud of. I think they're the best in the industry. And these new applications are working on a tremendous. The amount of interest we have related to semiconductors broadly and data centers and things all driven by I believe this overall AI investment in the use of AI. That I think is going to be a nice way for us and for anybody in this industry that's positioned for primarily in the metal side of the business. I think the ability to print basically heat sinks, heat conduction capabilities very, very positive. So you could see some large applications flowing through in the future for those. And that goes all the way down to semiconductor equipment manufacturing. We can consolidate the number of parts in a machine. These are extremely expensive machines, as you might know. We can consolidate number of parts. We can make them higher-performing parts all by 3D printing them and we so we've got all of the major, the semiconductor equipment manufacturers working with us. We have people that are using GPUs and data centers working with us. In fact at Formnext, I wish I'd put this on a slide. You would have seen a copper heat sink that was incredibly interesting. It's out on the website I believe, but it was designed using AI quite frankly and it can conduct heat away 3x more efficiently than any other high purity copper heat sink in the world. And so we're tremendously excited about markets like that, because they're very valuable high payoff components, which will help the whole supply chain. So I quoted the AIG rise not, because it's material impact on the P&L, but because the trend is really positive in terms of customer interest in 3D printing. So can't really help you from a timing standpoint on revenue specifically, but the trend is very positive.

Okay. That's great. Appreciate the color.

Okay. Stay warm, Danny. Have a good Thanksgiving.

Thank you. Our next question is coming from Troy Jensen from Cantor Fitzgerald. Your line is now live.

Hey, gentlemen. Thanks for taking my questions here. I guess, Jeff, one thing I picked up in at Formnext that I thought was kind of new is a lot of positive talk about Oqton. You did mention it in your kind of pre remarks, but can you just kind of talk, give us an update on software in general on 3DXpert?

Yes, sure, Troy. And thanks for the call and thanks for the interest in Formnext too. Yes, you asked about two things there and I'd throw in a third. So our 3D Sprint software, which drives our polymer machines and 3DXpert on the metal side, are tremendously valuable tools for people that want to apply 3D printing. What we've done now with Oqton is basically integrate 3DXpert into the Oqton workflow and we've really targeted and focused Oqton on the high reliability markets like oil & gas we're doing with Baker Hughes and others. But the vast software platform Troy will allow us to monitor the entire workflow, not us, but customers that lets them monitor the entire workflow from raw materials to finished part. And what we're seeing in the Baker Hughes production lines right now is a tremendous improvement in the productivity and quality of parts they can get out. The real-time monitoring, the feedback control, the traceability required. So it impacts everything from setup time to the time a part is produced and it gives you full traceability of the part when it's finished. So we're making 3D printing a true production process with this. Interesting feedback from Baker Hughes as also a customer of the software was this industry is now starting to really think about how to use 3D printing in production, whereas before it mainly went into laboratories for prototyping and even demo parts. Now it's being used on the factory floor. Those requirements are so different and so much more rigorous in terms of monitoring the job, monitoring the actual production of the parts. So I'm really pleased with Oqton’s progress. I think we'll demo it very nicely with Baker Hughes and then we're rolling it out broadly to other primarily industrial applications that have to make high reliability parts. So energy, aero, certainly the medical markets, anybody that has to make a high reliability part at high productivity.

Okay, how about two other questions here. Did you have a 10% customer in the quarter?

We do. Jeff, I have to, yes, I'm sure, I don't have the number in front of me, Troy, but it would be in our queue, I believe, Jeff, right? So it's in our queue. And certainly it would be related to dental, Troy, as it has been historically true. So that relationship remains very strong. The indirect printing of aligners is a great way to make them. And we continue to be a key supplier in that market. So yes, I mean, and I don't have a number, Troy, but it's in the queue and we can certainly get back to you.

Yes, I'm just glad to hear they're back. And then just last question, regenerative business, can you just talk about when you expect to hit the next milestones?

Yes, Troy, I think we'll see some additional milestones in ‘25. I wish we could talk more about it, both the precision and the speed at which we can print extremely fine structure now is amazing. And we have multiple paths to the design of those printers for production applications for organs and the human body, specifically lungs. So I am really pleased with progress on the technology and the implementation of that for lung manufacturing. So you can expect, we'll be talking about milestones in 2025 that we're hitting and I continue to believe we're on track to be in a position to get to human demonstration on a reasonable timeline. United Therapeutics, our partner in this, will have to speak to that milestone. But in terms of the printing technology and things and the materials that go with it, extremely pleased with progress. And Troy, just one more advertisement for that. It's really cool applications that are going to bring a lot of benefit to humanity. It's also generating some great technology that we can transition into our industrial printers. For example, the PSLA with this high precision projection system over VAT, that's a direct outgrowth of our work on regenerative. So if you take a hardened projector that's used for industrial applications for workflow, it's a direct transfer and a drop-in. So you'll see some real technology synergy coming out of our work on regenerative into our industrial markets.

Awesome. All right, guys. Good luck going forward. Happy Thanksgiving.

Thanks, Troy. Happy Thanksgiving to you too, bud.

Thank you. Our next question is coming from Ananda Baruah from Loop Capital Markets. Your line is now live.

Good morning, Ananda.

Good morning. Good morning. Yes, thanks for taking the question. Happy Thanksgiving. Yes, appreciate you guys taking the question here. I guess a couple if I could, the first is on just sort of the core health care business and industrial solutions. Sort of taking it backwards, sort of the softer sell-out, notwithstanding, you guys do seem like the last three quarters, you kind of baselined, you know, at this high-50s, low-60s run rate? And in healthcare, you've picked up both, because of the dental business and then also here's kind of a question, is there anything in personalized health care as distinct from dental that we should be aware of? And so really with that as a backdrop and sort of the supplies business continuing to grow? What does the baseline business look like into ‘25? Understanding, Jeff, you're not given guidance yet. But if industrial solutions is baseline right now, and if you're seeing a pickup in healthcare, and if you're also seeing a pickup, ongoing growth in supplies, what does that say structurally about going into ‘25?

Yes, I’ll start with the last point. All of this suggests that 2025 should be a better year. As long as the geopolitical climate stabilizes and economies continue to progress, we can remain optimistic. However, there are uncertainties with changes in administrations in the U.S. and possibly other countries, as well as ongoing conflicts. Despite these unknowns, trends are positively moving for printer platform sales and consumable sales in the future. We hope to be in a position to announce stronger results for 2025 when we report Q4. Additionally, we see meaningful cost management opportunities ahead. We have consistently invested in R&D, which is now showing returns, and we plan to optimize our cost structure in 2025. There are real opportunities both internally and in the broader environment. In healthcare, we have a solid business, especially in orthopedics and surgical planning for bone repair. We’re gaining FDA approvals for various applications in the body, maintaining strength above the neck and growing our presence below it. We expect continued growth, despite potential fluctuations quarter to quarter. The dental business is also strong, particularly with indirect aligners, and we anticipate new products, including dentures, which fit well within our strengths in 3D printing. I'm excited about the prospects for dentures in 2025, along with other dental applications like night guards. The healthcare space remains a core focus for us. On the industrial side, we’re seeing a surge of interest in high-reliability markets from customers, and I hope to see capital investment from them in 2025 as the benefits are clear. This ties back to the global economy and factory utilization. I hope this addresses your questions, and I’m happy to clarify anything further.

No, that's really great. And just a quick follow-up on tariffs. Anything to be aware of in the tariffs that have been announced so far, or supposed to be announced?

Yes. You know, Ananda. Yes, it's very interesting, and this is all public. If you look at the tariffs that have been talked about, and particularly with respect to China, the Chinese metal printing companies have sprung up over the years and I think, you know, aimed toward Chinese markets and others, they're increasingly looking to export those products into the U.S. and you know, a lot of the U.S. applications are defense-oriented. So I think both the tariff situation and the focus on defense will help us as a U.S. company. I think that's a great thing, because the influx of those printers, and I've shared this information, it's all publicly available, has been high. And I would hope as on-shoring and supply chain shortening effects take hold, if we do see tariffs coming in, and certainly the growth in defense and aerospace, those are all positives for us as a U.S. company.

Super helpful. Thanks a lot. Have a great holiday, you guys.

Thanks, Ananda. You have a great Thanksgiving as well.

Thank you. Our next question is from Brian Drab from William Blair. Your line is now live.

Good morning, Tyler here filling in for Brian. It was great color in the data center equipment. Sounds like additive would be great for the cold plates that go on GPUs and the other data center infrastructure? But I only have two questions today. First, what are your plans for convertible debt coming due in 2026? And then second, you mentioned a target of mid-40s gross margin? What revenue rate would need to be to support those levels? Assuming that on historically similar revenue levels going forward, you'd probably do higher margin just driven by the insourcing efforts. If you could just elaborate on that situation, appreciate the time and Happy Thanksgiving.

Thanks so much for the question and a happy Thanksgiving to you as well. So you touched on the key points. It's the factory, basically our gross margins, if you look at COGS, that's going to be a direct outgrowth of factory volumes and the increased benefit from insourcing. So, you know, it clearly, as volumes rise, it's a good thing for factory utilization rates. And the other benefit that brings us is a lower propensity to write down inventory. We absorbed, the reality is, we absorbed a lot of inventory when we insourced manufacturing aggressively over the last two years. And I would tell you for everybody listening to this call, I think it's a tremendous move for a low volume, high mix company like ours in this industry. Taking full control over your product from the start of design to the time you ship and install to a customer is critically important in controlling the pace of new product introduction and the quality of the product you ship. I firmly believe that. So we spent great effort in sourcing and unfortunately with that we had to absorb a lot of inventory from our contract manufacturing partners that they had purchased due to just aging of the parts. They don't go bad, but they age out according to your policy. So we had some headwinds on the last two quarters from that. Hopefully as volumes pick up, that effect, that kind of over the top effect will go away. And you'll see improvements in factory utilization. So both those will really help gross margin significantly. And then on top of that, we're rolling out new materials all the time. So new consumables, we're also really driving services because the customers that have factories want great service. So the increase in services revenue, the increase in materials revenue will all support higher gross margins. So fundamentally those are the levers. And I have no doubt we can get to mid-40%s, that's our near-term goal. We have a long-term goal of getting over 50%, which given the growth in metals in the world right now and the relatively lower materials pull through on metals, that's a challenge. But we're getting there. We're headed that direction. And I have confidence over the long-term we will get there. And then eventually metals, some of the metal materials will probably evolve to match 3D printing as well. But for now there's not a lot of materials pulled through from our standpoint on the metal side. So it is a drag on the overall gross margin. But we're getting there. It's improving. And I'm thrilled to have both metals and polymers in our portfolio. Some of the most exciting applications we're seeing on the industrial side are hardcore metal applications with difficult materials like copper, which are hard to print. So, long-winded way of saying those are the elements that get us to mid-40s and then up to 50%, which is our ultimate goal.

Thank you, Jeff. That's great color. I just wanted to follow-up on the plans for the convertible debt coming due in 2026? Just any color you can write there? Thank you.

Yes, it's certainly a work in progress, I would tell you right now. I mean, that's been a lovely debt instrument for us. We obviously went to market at a great time, and it's a zero coupon piece of paper. It's been terrific for us. It will come due at some point. We've got to deal with that. And so we're looking at how do we do that with the most traditional methods we can. Okay, so we're looking at how we can really reduce that debt. I'm not in a position to talk about it today, but clearly we want to deal with it as early as possible and not get toward maturity dates. So you'll hear a lot more about that in ‘25, okay?

All right, sounds good. Looking forward to 2025 for you guys and have a Happy Thanksgiving again.

Thank you and Happy Thanksgiving to you and Brian as well.

Thank you. Next question is coming from Jacob Stephan from Lake Street Capital Markets. Your line is now live.

Hey, good morning, guys. Thanks for taking my questions. I'm just curious on the healthcare business. Obviously, nice to see that return to growth this quarter. But, you know, maybe just kind of give us a sense on the order patterns now that we're kind of two-thirds of the way through Q4? I mean, do you feel like, you know, kind of the revenue level where you guys were at in Q3 here is a good, I guess, a place to build off of, or do you expect the stability here?

Good morning, Jacob, and happy upcoming Thanksgiving. I appreciate you reaching out today. I believe this provides a solid foundation for growth. The orthopedic segment of our healthcare business is steady and reliable. We are focusing on two main strategies to expand: developing more applications for the skeleton below the neck and working closely with the FDA to obtain necessary certifications. This segment is thriving and continues to show consistent growth. We are also excited to move into the trauma field with our channel partners, allowing us to apply our technology in urgent situations that require quick treatment. While our performance in the U.S. has been stronger compared to Europe, Europe remains a key focus for growth, alongside other global markets. Overall, I am optimistic about the various growth opportunities we see. The foundation of our healthcare business is strong, with a solid brand presence, and I anticipate continued growth. The dental sector, on the other hand, is somewhat more unpredictable. We have historically focused on indirect printing of aligners, but we are now expanding into dentures and other areas, which may lead to some volatility as market conditions change. However, this diversification will benefit our dental portfolio in the long run, and we expect to see positive developments over the next couple of years. While there may be fluctuations from quarter to quarter, I remain confident that our healthcare business will continue to grow, and I’m pleased to be part of it.

Got it. And then maybe just kind of on the I guess insourcing initiative you know requiring more inventory to be repurchased back from your contract manufacturers. I'm just curious you know I guess what percentage of that kind of inventory surplus was repurchased from the contract manufacturers and any…

We had to repurchase over $100 million of inventory and I wasn't pleased with the inventory management, supply chain management, and product quality from our contract manufacturers. These factors led us to bring 80% to 90% of our business in-house, primarily in South Carolina, with some manufacturing in Europe. As part of this transition, we needed to buy the inventory they had acquired for us, resulting in a manageable increase in our inventory levels. We will continue to reduce this inventory, aiming for a 20% reduction by the end of the year, though the low sales environment has made this challenging. On the positive side, reducing inventory is a good source of cash and allows us to make investments since we had sufficient cash on hand. As we reduce inventory, we expect to see benefits both in cash flow and in gross margins.

Hey got it very helpful. I appreciate all the color. Happy Thanksgiving and looking forward to ‘25 for you guys.

We are too. Thanks so much for calling in.

Thank you. We've reached the end of our question-and-answer session. I'd like to turn the floor back over to Jeff for any further closing comments.

Hey, Kevin, first of all, I want to wish you a very Happy Thanksgiving as well. You've been terrific at moderating our calls for many, many quarters now, so thank you for that. And for everybody else that's tuned in, I want to thank you all for joining our call today. For those of the U.S., I wish you all a happy and safe Thanksgiving holiday with your families. For those outside of the U.S., I wish you a very happy holiday season coming up. We'll look forward to talking to you again, at least in the new year.

Thank you. That does conclude today's teleconference and webcast. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today.